Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases

Nathan J. Wittenberg; Bharath Wootla; Luke R. Jordan; Aleksandar Denic; Arthur E. Warrington; Sang Hyun Oh; Moses Rodriguez

doi:10.1586/14737175.2014.896199

Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases

Nathan J. Wittenberg, Bharath Wootla, Luke R. Jordan, Aleksandar Denic, Arthur E. Warrington, Sang Hyun Oh, Moses Rodriguez

Electrical and Computer Engineering

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Characterization of binding kinetics and affinity between a potential drug and its receptor are key steps in the development of new drugs. Among the techniques available to determine binding affinities, surface plasmon resonance has emerged as the gold standard because it can measure binding and dissociation rates in real-time in a label-free fashion. Surface plasmon resonance is now finding applications in the characterization of molecules for treatment of neurodegenerative diseases, characterization of molecules associated with pathogenesis of neurodegenerative diseases and detection of neurodegenerative disease biomarkers. In addition it has been used in the characterization of a new class of natural autoantibodies that have therapeutic potential in a number of neurologic diseases. In this review we will introduce surface plasmon resonance and describe some applications of the technique that pertain to neurodegenerative disorders and their treatment.

Original language	English (US)
Pages (from-to)	449-463
Number of pages	15
Journal	Expert Review of Neurotherapeutics
Volume	14
Issue number	4
DOIs	https://doi.org/10.1586/14737175.2014.896199
State	Published - Apr 2014

Bibliographical note

Funding Information:
This work was supported by grants from the NIH (R01 GM092993, R01 NS048357 and R21 NS073684) and the National Multiple Sclerosis Society (CA 1060A). This work was also supported by a High-Impact Pilot and Feasibility Award (HIPFA) and Novel Methodology Award (NMDA) from the Mayo Clinic Center for Translational Science Activities (CTSA) and Mayo Clinic CTSA grant number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). We also acknowledge with thanks support from the Applebaum, Hilton, Peterson and Sanford Foundations, the Minnesota Partnership Award for Biotechnology and Medical Genomics, the Moon and Marilyn Park Directorship Fund and the McNeilus family.

Keywords

Alzheimer's disease
Amyloid-beta
Antibodies
Biomarkers
Lipid bilayer membrane
Multiple sclerosis
Neuromyelitis optica
Surface modification
Surface plasmon resonance

Access

10.1586/14737175.2014.896199

OpenUrl availability

Full text

Cite this

@article{b4e276fa43c243d08b94341f366808cd,

title = "Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases",

abstract = "Characterization of binding kinetics and affinity between a potential drug and its receptor are key steps in the development of new drugs. Among the techniques available to determine binding affinities, surface plasmon resonance has emerged as the gold standard because it can measure binding and dissociation rates in real-time in a label-free fashion. Surface plasmon resonance is now finding applications in the characterization of molecules for treatment of neurodegenerative diseases, characterization of molecules associated with pathogenesis of neurodegenerative diseases and detection of neurodegenerative disease biomarkers. In addition it has been used in the characterization of a new class of natural autoantibodies that have therapeutic potential in a number of neurologic diseases. In this review we will introduce surface plasmon resonance and describe some applications of the technique that pertain to neurodegenerative disorders and their treatment.",

keywords = "Alzheimer's disease, Amyloid-beta, Antibodies, Biomarkers, Lipid bilayer membrane, Multiple sclerosis, Neuromyelitis optica, Surface modification, Surface plasmon resonance",

author = "Wittenberg, {Nathan J.} and Bharath Wootla and Jordan, {Luke R.} and Aleksandar Denic and Warrington, {Arthur E.} and Oh, {Sang Hyun} and Moses Rodriguez",

note = "Funding Information: This work was supported by grants from the NIH (R01 GM092993, R01 NS048357 and R21 NS073684) and the National Multiple Sclerosis Society (CA 1060A). This work was also supported by a High-Impact Pilot and Feasibility Award (HIPFA) and Novel Methodology Award (NMDA) from the Mayo Clinic Center for Translational Science Activities (CTSA) and Mayo Clinic CTSA grant number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). We also acknowledge with thanks support from the Applebaum, Hilton, Peterson and Sanford Foundations, the Minnesota Partnership Award for Biotechnology and Medical Genomics, the Moon and Marilyn Park Directorship Fund and the McNeilus family.",

year = "2014",

month = apr,

doi = "10.1586/14737175.2014.896199",

language = "English (US)",

volume = "14",

pages = "449--463",

journal = "Expert Review of Neurotherapeutics",

issn = "1473-7175",

publisher = "Expert Reviews Ltd.",

number = "4",

}

TY - JOUR

T1 - Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases

AU - Wittenberg, Nathan J.

AU - Wootla, Bharath

AU - Jordan, Luke R.

AU - Denic, Aleksandar

AU - Warrington, Arthur E.

AU - Oh, Sang Hyun

AU - Rodriguez, Moses

N1 - Funding Information: This work was supported by grants from the NIH (R01 GM092993, R01 NS048357 and R21 NS073684) and the National Multiple Sclerosis Society (CA 1060A). This work was also supported by a High-Impact Pilot and Feasibility Award (HIPFA) and Novel Methodology Award (NMDA) from the Mayo Clinic Center for Translational Science Activities (CTSA) and Mayo Clinic CTSA grant number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). We also acknowledge with thanks support from the Applebaum, Hilton, Peterson and Sanford Foundations, the Minnesota Partnership Award for Biotechnology and Medical Genomics, the Moon and Marilyn Park Directorship Fund and the McNeilus family.

PY - 2014/4

Y1 - 2014/4

N2 - Characterization of binding kinetics and affinity between a potential drug and its receptor are key steps in the development of new drugs. Among the techniques available to determine binding affinities, surface plasmon resonance has emerged as the gold standard because it can measure binding and dissociation rates in real-time in a label-free fashion. Surface plasmon resonance is now finding applications in the characterization of molecules for treatment of neurodegenerative diseases, characterization of molecules associated with pathogenesis of neurodegenerative diseases and detection of neurodegenerative disease biomarkers. In addition it has been used in the characterization of a new class of natural autoantibodies that have therapeutic potential in a number of neurologic diseases. In this review we will introduce surface plasmon resonance and describe some applications of the technique that pertain to neurodegenerative disorders and their treatment.

AB - Characterization of binding kinetics and affinity between a potential drug and its receptor are key steps in the development of new drugs. Among the techniques available to determine binding affinities, surface plasmon resonance has emerged as the gold standard because it can measure binding and dissociation rates in real-time in a label-free fashion. Surface plasmon resonance is now finding applications in the characterization of molecules for treatment of neurodegenerative diseases, characterization of molecules associated with pathogenesis of neurodegenerative diseases and detection of neurodegenerative disease biomarkers. In addition it has been used in the characterization of a new class of natural autoantibodies that have therapeutic potential in a number of neurologic diseases. In this review we will introduce surface plasmon resonance and describe some applications of the technique that pertain to neurodegenerative disorders and their treatment.

KW - Alzheimer's disease

KW - Amyloid-beta

KW - Antibodies

KW - Biomarkers

KW - Lipid bilayer membrane

KW - Multiple sclerosis

KW - Neuromyelitis optica

KW - Surface modification

KW - Surface plasmon resonance

UR - http://www.scopus.com/inward/record.url?scp=84896355006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896355006&partnerID=8YFLogxK

U2 - 10.1586/14737175.2014.896199

DO - 10.1586/14737175.2014.896199

M3 - Review article

C2 - 24625008

AN - SCOPUS:84896355006

SN - 1473-7175

VL - 14

SP - 449

EP - 463

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

IS - 4

ER -

Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this